Participant flow20

How many started, completed or left each group, period by period.

1 to 20 of 20

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	89
Overall Study	STARTED	Romosozumab 70 mg	60
Overall Study	STARTED	Romosozumab 140 mg	93
Overall Study	STARTED	Romosozumab 210 mg	90
Overall Study	Received Study Drug	Placebo	87
Overall Study	Received Study Drug	Romosozumab 70 mg	60
Overall Study	Received Study Drug	Romosozumab 140 mg	89
Overall Study	Received Study Drug	Romosozumab 210 mg	89
Overall Study	Completed 24 Weeks of Study	Placebo	73
Overall Study	Completed 24 Weeks of Study	Romosozumab 70 mg	50
Overall Study	Completed 24 Weeks of Study	Romosozumab 140 mg	72
Overall Study	Completed 24 Weeks of Study	Romosozumab 210 mg	68
Overall Study	COMPLETED	Placebo	62
Overall Study	COMPLETED	Romosozumab 70 mg	44
Overall Study	COMPLETED	Romosozumab 140 mg	62
Overall Study	COMPLETED	Romosozumab 210 mg	61
Overall Study	NOT COMPLETED	Placebo	27
Overall Study	NOT COMPLETED	Romosozumab 70 mg	16
Overall Study	NOT COMPLETED	Romosozumab 140 mg	31
Overall Study	NOT COMPLETED	Romosozumab 210 mg	29

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01081678/flow